子查询返回的值不止一个。当子查询跟随在 =、!=、<、<=、>、>= 之后，或子查询用作表达式时，这种情况是不允许的。 小细胞肺癌患者化疗前后CEA、NSE和CYFRA21-1的变化对评估预后的作用-《天津医科大学学报》
|本期目录/Table of Contents|

[1]李家腾,宋世辉,王 田,等.小细胞肺癌患者化疗前后CEA、NSE和CYFRA21-1的变化对评估预后的作用[J].天津医科大学学报,2014,20(06):448-452.
　LI Jia-teng,SONG Shi-hui,WANG Tian,et al.Effect of Changes of CEA, NSE and CYFRA21-1 before and after chemotherapy on the evaluation of prognosis in patients with small cell lung cancer[J].Journal of Tianjin Medical University,2014,20(06):448-452.
点击复制

小细胞肺癌患者化疗前后CEA、NSE和CYFRA21-1的变化对评估预后的作用(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
20卷
期数:
2014年06期
页码:
448-452
栏目:
临床医学
出版日期:
2014-11-20

文章信息/Info

Title:
Effect of Changes of CEA, NSE and CYFRA21-1 before and after  chemotherapy on the evaluation of prognosis in patients with small cell lung cancer
文章编号:
1006-8147（2014）06-0448-05
作者:
李家腾; 宋世辉; 王 田; 闫庆贺
(天津医科大学总医院胸外科, 天津 300052)
Author(s):
LI Jia-teng;  SONG Shi-hui;  WANG Tian;  YAN Qing-he
(Department of Thoracic Surgery ,General Hospital, Tianjin Medical University,Tianjin 300052, China)
关键词:
小细胞肺癌; 化疗; CEA; NSE; CYFRA21-1; 预后
Keywords:
small cell lung cancer;  chemotherapy;  CEA;  NSE;  CYFRA21-1;  prognosis
分类号:
R734.2
DOI:
-
文献标志码:
A
摘要:
目的：探讨小细胞肺癌患者(SCLC)化疗前及化疗后血清CEA、NSE和CYFRA21-1变化在患者预后中的预测作用。方法: 采用ELISA法检测63例病理确诊小细胞肺癌患者化疗前和两周期化疗后血清中CEA、NSE和CYFRA21-1的含量变化，化疗结束随访患者生存期。结果：全组患者平均生存时间为（21±4）月，中位生存时间为22月， 1、2、3年生存率分别为76.2%、41.3%和14.3%。两周期化疗后CEA、NSE和CYFRA21-1水平降低的患者平均生存期分别为（25.7±3.5）月、（25.3±4.5）月、（24.5±5.3）月，明显较化疗后肺肿瘤标志物不降低患者平均生存期（16.0±3.9）月(P<0.01)、（13.7±3.4）月(P<0.01)、（16.7±3.2）月(P<0.05)高，其1、2、3年生存率也有显著差异。结论：化疗后CEA、NSE和CYFRA21-1水平降低的患者生存期较不降低患者高，监测小细胞肺癌患者化疗前后肺肿瘤标志物的变化有助于评价患者对化疗药物敏感性及评估患者预后。
Abstract:
Objective: To investigate the significance of serum CEA，NSE and CYFRA21-1 changes in chemotherapy in the prognosis of small-cell lung cancer (SCLC)patient. Methods: ELISA was used to detect content changes in serum CEA, NSE and CYFRA21-1 before and after two cycles of chemotherapy in the 63 patients with pathologically confirmed SCLC. Survival time of the patients after chemotherapy were followed up. Results: The average survival time was （21±4）months, the median survival time was 22 months， and 1 ，2，3 year survival rates were 76.2%, 41.3% and 14.3%.After two cycles of chemotherapy ， CEA，NSE and CYFRA21-1 levels reduced in patients with an average survival time of （25.7±3.5） months, （25.3±4.5） months, （24.5±5.3） months , significantly higher than patients whose levels was not reduced with an average survival time of （16.0±3.9）months (P <0.01), (13.7±3.4) months (P <0.01), (16.7±3.2) months (P <0.05). Furthermore, 1, 2, 3-year survival rates were also significantly different. Conclusion: The survival time of patients with reduced CEA, NSE and CYFRA21-1 in chemotherapy are higher than the patients who are not. Monitoring changes of lung tumor markers in chemotherapy in SCLC can help to assess chemotherapy-sensitive and evaluate the prognosis of patients.

参考文献/References:

[1]Li J, Dai C H, Chen P, et al. Survival and prognostic factors in small cell lung ancer[J]. Med Oncol, 2010,27(1):73
[2]Wu C, Li F, Jiao S C. Prognostic factors for survival of patients with extensive stage small cell lung cancer--a retrospective single institution analysis[J]. Asian Pac J Cancer Prev, 2012,13(10):4959
[3]Harmsma M, Schutte B, Ramaekers F C. Serum markers in small cell lung Cancer: opportunities for improvement[J]. Biochim Biophys Acta, 2013,1836(2):255
[4]Hirose T, Okuda K, Yamaoka T, et al. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung Cancer[J]. Lung Cancer, 2011,71(2):224
[5]Jan P, Dean A, Dirk K. Small-cell lung cancer.[J]. The Lancet, 2011,378(11):1741
[6]Chan B A, Coward J I. Chemotherapy advances in small-cell lung cancer[J]. J Thorac Dis, 2013,5(Suppl 5):S565
[7]Puglisi M, Dolly S, Faria A, et al. Treatment options for small cell lung Cancer - do we have more choice?[J]. Br J Cancer, 2010,102(4):629
[8]Kalemkerian, P G. Staging and imaging of small cell lung cancer[J]. Cancer Imaging, 2011,11(2):253
[9]Holdenrieder S, von Pawel J, Dankelmann E, et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung Cancer[J]. Clin Cancer Res, 2008,14(23):7813
[10]Ahmet E, Ayriz G, Zeynep Z. Pre-treatment and treatment-induced neuron-specific enolase in patients [J]. Archivos de Bronconeumología, 2010,46(7):364
[11]Ewa W, Jan K, Beata S. ProGRP and NSE in therapy monitoring[J]. Anticancer Res, 2008,28(9):3027
[12]Soichiro A, Makoto S, Naoyoshi Y, et al. The prognostic value of both neuron-specific enolase (NSE) [J]. Anticancer Res, 2004,24(4):1941
[13]Schreiber D, Rineer J, Weedon J, et al. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated[J]. Cancer, 2010,116(5):1350
[14]Lim E, Belcher E, Yap Y K, et al. The role of surgery in the treatment of limited disease small cell lung Cancer: time to reevaluate[J]. J Thorac Oncol, 2008,3(11):1267
[15]Haddadin S, Perry M C. History of Small-Cell lung cancer[J]. Clin Lung Cancer, 2011,12(2):87
[16]Kim H R, Oh I J, Shin M G, et al. Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer[J]. J Korean Med Sci, 2011,26(5):625

相似文献/References:

[1]闫庆贺,宋世辉,彭 民,等.卡铂联合多西他赛治疗非小细胞肺癌CECs变化[J].天津医科大学学报,2014,20(05):366.
　YAN Qing-he,SONG Shi-hui,PENG Min,et al.Changes of circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin plus docetaxel[J].Journal of Tianjin Medical University,2014,20(06):366.
[2]王冬冬,秦振邦,王晓明,等.成人I期原发睾丸畸胎瘤预后分析[J].天津医科大学学报,2016,22(03):265.
[3]仝颖娜,刘晓彬,张露方,等.血胱抑素C等对肺癌患者化疗过程中肾损伤的评价[J].天津医科大学学报,2017,23(02):143.
　TONG Ying-na,LIU Xiao-bin,ZHANG Lu-fang,et al.Evaluation of serum cystatin C in kidney function damage for patients with lung cancer during chemotherapy[J].Journal of Tianjin Medical University,2017,23(06):143.
[4]刘欣,张鹏,陈渊.肠内营养支持在食管癌术后辅助化疗患者中的临床应用[J].天津医科大学学报,2017,23(03):274.
[5]王子乔,张雪茜,孟凡荣,等.小鼠小细胞肺癌模型的建立[J].天津医科大学学报,2018,24(01):29.
　WANG Zi-qiao,ZHANG Xue-xi,MENG Fan-rong,et al.Establishment of a mouse model of pulmonary small cell lung cancer[J].Journal of Tianjin Medical University,2018,24(06):29.
[6]张姝阳,张家丽,赵 宁,等.IP方案与CAO方案二线治疗复发小细胞肺癌的疗效及毒副作用比较研究[J].天津医科大学学报,2018,24(05):415.
　ZHANG Shu-yang,ZHANG Jia-li,ZHAO Ning,et al.Comparison of the efficacy and toxicity between the IP regimen and the CAO regimen in the second line treatment for recurrent small cell lung cancer[J].Journal of Tianjin Medical University,2018,24(06):415.
[7]董傲然,张家丽,任秀宝,等.促胃泌素释放肽前体对小细胞肺癌的诊断价值[J].天津医科大学学报,2019,25(03):234.
　DONG Ao-ran,ZHANG Jia-li,REN Xiu-bao,et al.Diagnosis value of pro-gastrin-releasing peptide precursor for small cell lung cancer[J].Journal of Tianjin Medical University,2019,25(06):234.
[8]赵军华,邱鸣寒,袁智勇.射波刀治疗小细胞肺癌脑转移的疗效分析[J].天津医科大学学报,2019,25(04):346.
　ZHAO Jun-hua,QIU Ming-han,YUAN Zhi-yong.The effectiveness of CyberKnife for brain metastases from small cell lung cancer[J].Journal of Tianjin Medical University,2019,25(06):346.
[9]胡 雪 综 述,张新伟 审 校.小细胞肺癌合并低钠血症的研究进展[J].天津医科大学学报,2019,25(04):422.
[10]高会霞,王 彬,方 黎,等.3DCRT联合化疗对晚期NSCLC患者近期疗效及血清肿瘤标记物的影响[J].天津医科大学学报,2019,25(05):507.

备注/Memo

备注/Memo:
作者简介 李家腾（1988-），男，硕士在读，研究方向：胸心外科；通信作者：宋世辉，E-mail：xwsongshihui@126.com。

更新日期/Last Update: 2014-11-21